Biohaven Statistics
Total Valuation
Biohaven has a market cap or net worth of $1.33 billion. The enterprise value is $1.33 billion.
Important Dates
The last earnings date was Monday, November 10, 2025, before market open.
| Earnings Date | Nov 10, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Biohaven has 132.69 million shares outstanding. The number of shares has increased by 19.62% in one year.
| Current Share Class | 132.69M |
| Shares Outstanding | 132.69M |
| Shares Change (YoY) | +19.62% |
| Shares Change (QoQ) | +3.36% |
| Owned by Insiders (%) | 12.23% |
| Owned by Institutions (%) | 65.39% |
| Float | 116.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 117.16 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.86
| Current Ratio | 2.86 |
| Quick Ratio | 2.30 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -522.08% and return on invested capital (ROIC) is -152.19%.
| Return on Equity (ROE) | -522.08% |
| Return on Assets (ROA) | -106.25% |
| Return on Invested Capital (ROIC) | -152.19% |
| Return on Capital Employed (ROCE) | -263.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.05M |
| Employee Count | 256 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Biohaven has paid $1.14 million in taxes.
| Income Tax | 1.14M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -78.40% in the last 52 weeks. The beta is 3.45, so Biohaven's price volatility has been higher than the market average.
| Beta (5Y) | 3.45 |
| 52-Week Price Change | -78.40% |
| 50-Day Moving Average | 13.49 |
| 200-Day Moving Average | 18.15 |
| Relative Strength Index (RSI) | 42.48 |
| Average Volume (20 Days) | 6,498,807 |
Short Selling Information
The latest short interest is 13.13 million, so 9.89% of the outstanding shares have been sold short.
| Short Interest | 13.13M |
| Short Previous Month | 10.30M |
| Short % of Shares Out | 9.89% |
| Short % of Float | 11.27% |
| Short Ratio (days to cover) | 2.57 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -781.68M |
| Pretax Income | -778.97M |
| Net Income | -780.11M |
| EBITDA | -771.87M |
| EBIT | -781.68M |
| Earnings Per Share (EPS) | -$7.59 |
Full Income Statement Balance Sheet
The company has $260.22 million in cash and $314.18 million in debt, giving a net cash position of -$53.96 million or -$0.41 per share.
| Cash & Cash Equivalents | 260.22M |
| Total Debt | 314.18M |
| Net Cash | -53.96M |
| Net Cash Per Share | -$0.41 |
| Equity (Book Value) | -17.16M |
| Book Value Per Share | -0.16 |
| Working Capital | 210.59M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$649.52 million and capital expenditures -$756,000, giving a free cash flow of -$650.27 million.
| Operating Cash Flow | -649.52M |
| Capital Expenditures | -756,000 |
| Free Cash Flow | -650.27M |
| FCF Per Share | -$4.90 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biohaven does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -19.62% |
| Shareholder Yield | -19.62% |
| Earnings Yield | -61.08% |
| FCF Yield | -50.92% |
Dividend Details Analyst Forecast
The average price target for Biohaven is $31.14, which is 210.78% higher than the current price. The consensus rating is "Buy".
| Price Target | $31.14 |
| Price Target Difference | 210.78% |
| Analyst Consensus | Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -46.22% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |